Comparison

Liraglutide vs. Pemvidutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Evidence base

Highest evidence

Human RCT

Human trial

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Pemvidutide
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Liraglutide and Pemvidutide?: Liraglutide is classified as "Metabolic", while Pemvidutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Pemvidutide?: The highest available evidence level is "Human RCT" for Liraglutide and "Human trial" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Pemvidutide in Germany and the United States?: Germany: Liraglutide — Prescription, Pemvidutide — Unapproved. United States: Liraglutide — Prescription, Pemvidutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Pemvidutide

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Liraglutide and Pemvidutide?

Liraglutide is classified as "Metabolic", while Pemvidutide is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Pemvidutide?

The highest available evidence level is "Human RCT" for Liraglutide and "Human trial" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Pemvidutide in Germany and the United States?

Germany: Liraglutide — Prescription, Pemvidutide — Unapproved. United States: Liraglutide — Prescription, Pemvidutide — Unapproved. These are factual summaries with source and review date on the individual pages.